Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4250054 | 0.82 | ALDH1A1 (0.39) | PLA2G2CNLRP3USP2TSHR | |
| SCHEMBL10669272 | 0.80 | ALDH1A1 (0.46) | PLA2G2CNLRP3TSHR | |
| SCHEMBL10827151 | 0.80 | NLRP3 (0.32) | NLRP3USP2TSHR | |
| SCHEMBL10669266 | 0.78 | NLRP3 (0.31) | NLRP3 | |
| SCHEMBL11316544 | 0.78 | NLRP3 (0.36) | NLRP3 | |
| SCHEMBL635545 | 0.78 | NLRP3 (0.31) | NLRP3 | |
| SCHEMBL112027 | 0.78 | LMNA (0.46) | NLRP3TSHR | |
| SCHEMBL16449384 | 0.78 | NLRP3 (0.31) | NLRP3 | |
| SCHEMBL10841258 | 0.78 | NLRP3 (0.31) | NLRP3 | |
| SCHEMBL9386508 | 0.77 | PTGS1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12467053-B2 | Hybrid immunoglobulins with moving parts | BIOMOLECULAR HOLDINGS LLC (US) | 2025-11-11 | — | — | US | disclosed |
| EP-3284825-B1 | METHODS OF PRODUCING HYBRID POLYPEPTIDES WITH MOVING PARTS | BIOMOLECULAR HOLDINGS LLC (US) | 2021-04-07 | — | — | EP | disclosed |
| US-20200032272-A1 | HYBRID IMMUNOGLOBULINS WITH MOVING PARTS | BIOMOLECULAR HOLDINGS LLC | 2020-01-30 | — | — | US | disclosed |
| US-10428332-B2 | Hybrid immunoglobulins with moving parts | BIOMOLECULAR HOLDINGS LLC | 2019-10-01 | — | — | US | disclosed |
| EP-3284825-A1 | METHODS OF PRODUCING HYBRID POLYPEPTIDES WITH MOVING PARTS | Capon, Daniel J. (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-2078040-B1 | Methods of producing hybrid polypeptides with moving parts | CAPON DANIEL J (US) | 2017-06-28 | — | — | EP | disclosed |
| US-20160376601-A1 | Hybrid immunoglobulins with moving parts | BIOMOLECULAR HOLDINGS LLC | 2016-12-29 | — | — | US | disclosed |
| WO-2008140477-A9 | HYBRID IMMUNOGLOBULINS WITH MOVING PARTS | CAPON DANIEL J (US) | 2009-10-15 | — | — | WO | disclosed |
| US-20090233806-A1 | Protein isolation and analysis | CARR FRANCIS J | 2009-09-17 | — | — | US | disclosed |
| EP-2078040-A2 | HYBRID IMMUNOGLOBULINS WITH MOVING PARTS | Capon, Daniel J. (US) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008140477-A2 | HYBRID IMMUNOGLOBULINS WITH MOVING PARTS | CAPON DANIEL J (US) | 2008-11-20 | — | — | WO | disclosed |
| US-20080254512-A1 | Hybrid immunoglobulins with moving parts | BIOMOLECULAR HOLDINGS LLC | 2008-10-16 | — | — | US | disclosed |
| US-7351540-B1 | Protein isolation and analysis | MERCK PATENT GMBH (DE) | 2008-04-01 | — | — | US | disclosed |
| EP-0098729-B1 | OXIME DERIVATIVES AND PROCESSES OF FORMING POLYMERIC OXIMES | POLAROID CORPORATION (US) | 1986-10-08 | — | — | EP | disclosed |
| US-4604460-A | ANTIBIOTICS, BACTERICIDES | SHIONOGI & CO., LTD. (JP) | 1986-08-05 | — | — | US | disclosed |
| US-4533730-A | BACTERICIDES | SHIONOGI & CO., LTD. (JP) | 1985-08-06 | — | — | US | disclosed |
| US-4504659-A | 1-Oxadethiacepham compounds | SHIONOGI & CO., LTD. (JP) | 1985-03-12 | — | — | US | disclosed |
| US-4478997-A | 1-Oxadethiacepham compounds | SHIONOGI & CO., LTD. (JP) | 1984-10-23 | — | — | US | disclosed |
| US-4443598-A | ANTIBIOTICS AND INTERMEDIATES | SHIONOGI & CO., LTD. (JP) | 1984-04-17 | — | — | US | disclosed |
| US-4366316-A | FROM OXAZOLINOAZETIDINONE AND ACID | SHIONOGI & CO., LTD. (JP) | 1982-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12467053-B2 | Hybrid immunoglobulins with moving parts | IGLV6-57, FCGRT, FCGR3B | PLA2G2C 498/4885NLRP3 1875/4885USP2 3965/4885 |
| US-10428332-B2 | Hybrid immunoglobulins with moving parts | FCGRT, IGLV6-57, FCGR3B | PLA2G2C 662/4885NLRP3 1927/4885USP2 3918/4885 |
| US-20080254512-A1 | Hybrid immunoglobulins with moving parts | FCGRT, IGLV6-57, FCGR3B | PLA2G2C 662/4885NLRP3 1927/4885USP2 3918/4885 |
| US-20200032272-A1 | HYBRID IMMUNOGLOBULINS WITH MOVING PARTS | IGLV6-57, FCGRT, FCGR3B | PLA2G2C 498/4885NLRP3 1875/4885USP2 3965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.